Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration

Hao Xie,Huan Ju,Jing Lu,Xing Wang,Hui Peng
DOI: https://doi.org/10.1038/s41598-024-62536-8
IF: 4.6
2024-05-27
Scientific Reports
Abstract:This study compares the effectiveness of Conbercept and Aflibercept in treating neovascular age-related macular degeneration (nAMD). Conducted at the First Affiliated Hospital of Chongqing Medical University's Ophthalmology Department (May 2020–May 2023), this prospective study enrolled 159 nAMD patients. Participants were randomly divided into two groups: one receiving 0.5 mg Conbercept and the other 2 mg Aflibercept intravitreal injections. Over 12 months, the study, employing a Treat-and-Extend (T&E) regimen, assessed Best-Corrected Visual Acuity (BCVA), Central Retinal Thickness (CRT) changes and injection frequency. Of the 159 patients, 137 (149 eyes) completed the study. No significant age difference was found between the groups (P = 0.331). After 12 months, BCVA improved similarly in both groups (Conbercept: 52.8 ± 18.9, Aflibercept: 52.0 ± 19.7 letters; P = 0.820). CRT reduction was also comparable (Conbercept: 246.3 ± 82.8 μm, Aflibercept: 275.9 ± 114.3 μm; P = 0.079). Injection frequencies averaged 6.9 ± 0.7 (Conbercept) and 6.7 ± 0.7 (Aflibercept; P = 0.255). Subtype analysis revealed Type 1 MNV had higher baseline BCVA and lower CRT, with more frequent injections compared to other types. Both Conbercept and Aflibercept are clinically similar in efficacy for nAMD, with the T&E regimen proving therapeutically effective and potentially reducing patient costs. Anti-VEGF treatment efficacy varies across nAMD subtypes, indicating a potential benefit in tailored treatments for specific subtypes.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to compare the efficacy of Conbercept and Aflibercept in the treatment of neovascular age - related macular degeneration (nAMD). The study evaluated the differences between the two drugs in best - corrected visual acuity (BCVA), central retinal thickness (CRT) changes, and injection frequency through a 12 - month prospective randomized controlled trial. ### Research Background Age - related macular degeneration (AMD) is the main cause of severe and irreversible vision loss in people over 55 years old. AMD is divided into two forms: dry and wet. Among them, wet AMD progresses more rapidly. It is accelerated by vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) to cause choroidal neovascularization (CNV) formation, and finally leads to retinal exudation, hemorrhage and central vision loss. ### Research Objectives The main objective of this study was to evaluate the differences in efficacy between Conbercept and Aflibercept in the treatment of nAMD, especially in terms of BCVA improvement, CRT reduction and injection frequency. The "Treat - and - Extend" (T&E) protocol was adopted in the study in order to reduce the treatment cost of patients. ### Methods - **Research Design**: This was a 12 - month randomized, phase IV clinical trial. A total of 159 nAMD patients were enrolled and randomly divided into two groups, receiving intravitreal injections of 0.5 mg Conbercept and 2 mg Aflibercept respectively. - **Sample Size Determination**: Based on the preliminary experimental results, 55 patients were required in each group. Considering a 15% loss - to - follow - up rate, 65 patients were finally required in each group, with a total of 130 patients. - **Evaluation Indicators**: The main evaluation indicators included BCVA, CRT changes and injection frequency. In addition, a subgroup analysis of different types of choroidal neovascularization (MNV) was also carried out. ### Results - **BCVA**: After 12 months, the BCVA improvement in the two groups was similar (Conbercept: 52.8 ± 18.9 letters, Aflibercept: 52.0 ± 19.7 letters; P = 0.820). - **CRT**: The CRT reduction in the two groups was also similar (Conbercept: 246.3 ± 82.8 μm, Aflibercept: 275.9 ± 114.3 μm; P = 0.079). - **Injection Frequency**: The average number of injections in the two groups was 6.9 ± 0.7 (Conbercept) and 6.7 ± 0.7 (Aflibercept; P = 0.255) respectively. - **Subgroup Analysis**: Type 1 MNV had a higher baseline BCVA, a lower CRT, and a higher injection frequency. Type 2 MNV had a lower baseline BCVA, but a lower injection frequency, and the visual improvement was not significantly inferior to other types. ### Discussion - **Drug Characteristics**: Conbercept is a recombinant fusion protein with high affinity and a long half - life, while Aflibercept is a fully humanized fusion protein that combines the domains of VEGFR - 1 and VEGFR - 2. Although there are differences in molecular structure between the two drugs, there are no significant differences in improving BCVA, reducing CRT and injection frequency. - **Treatment Protocol**: The T&E protocol may help to reduce the treatment cost of patients while maintaining the efficacy. - **Subtype Differences**: Different types of MNV have different responses to treatment, especially Type 1 and Type 2 MNV. Although patients with Type 1 MNV have a higher baseline BCVA, they require more frequent injections, while patients with Type 2 MNV have a lower baseline BCVA but a lower injection frequency. ### Conclusion Conbercept and Aflibercept have similar efficacies in the treatment of nAMD, and the T&E protocol has been proven to be effective in clinical practice. Future research can further explore personalized treatment strategies for specific subtypes.